Home » Stocks » LPTX

Leap Therapeutics, Inc. (LPTX)

Stock Price: $1.65 USD -0.04 (-2.37%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 98.44M
Revenue (ttm) 1.50M
Net Income (ttm) -37.59M
Shares Out 59.33M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.65
Previous Close $1.69
Change ($) -0.04
Change (%) -2.37%
Day's Open 1.68
Day's Range 1.59 - 1.69
Day's Volume 575,436
52-Week Range 1.43 - 3.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the comple...

2 weeks ago - PRNewsWire

Leap Therapeutics Inc (NASDAQ: LPTX) has announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanc...

3 weeks ago - Benzinga

CAMBRIDGE, Mass., March 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the prese...

3 weeks ago - PRNewsWire

Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -12.50% and -6.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial ...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougl...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the public...

3 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougl...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 10, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougl...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the present...

5 months ago - PRNewsWire

Two new breakout stocks for Week 46 with better than 10% short-term upside potential. This past week three out of four stocks gained more than 10% closing with gains to Friday with AVNS +8.54%, IMVT +14...

Other stocks mentioned: CBD, CSCO, CVX, HON, IBM, INTC, JPM ...
5 months ago - Seeking Alpha

CAMBRIDGE, Mass., Sept. 24, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the ...

6 months ago - PRNewsWire

CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, ...

6 months ago - PRNewsWire

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.

7 months ago - PRNewsWire

CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.

8 months ago - PRNewsWire

CAMBRIDGE, Mass., June 25, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closi...

9 months ago - PRNewsWire

CAMBRIDGE, Mass., June 17, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it ha...

10 months ago - PRNewsWire

Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U...

10 months ago - PRNewsWire

CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due...

10 months ago - PRNewsWire

CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial r...

11 months ago - PRNewsWire

Facing a de-listing from NASDAQ and forced to abandon its second clinical asset due to a cash crunch, Leap has rebounded somewhat on the back of a collaboration/financing deal.

1 year ago - Seeking Alpha

Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.

1 year ago - Zacks Investment Research

Leap Therapeutics (LPTX) news for Friday has LPTX stock soaring following a major deal with BeiGene for its DKN-01 antibody. The post Leap Therapeutics News: LPTX Stock Takes a Massive 58% Leap on BeiG...

1 year ago - InvestorPlace

Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.

Other stocks mentioned: ALDR, AMWD, COLM, DKS
1 year ago - Zacks Investment Research

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

Other stocks mentioned: AMRN, AZN, JAZZ, LGND, LXRX, PHAS, RHHBY ...
2 years ago - Benzinga

About LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and ... [Read more...]

Industry
Biotechnology
Founded
2011
Stock Exchange
NASDAQ
Ticker Symbol
LPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for LPTX stock is "Buy." The 12-month stock price forecast is 5.30, which is an increase of 221.21% from the latest price.

Price Target
$5.30
(221.21% upside)
Analyst Consensus: Buy